NCT00424892View on ClinicalTrials.gov

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 2007

Conditions
Fibromyalgia
Interventions
DRUG

Desvenlafaxine Sustained Release

Trial Locations (59)

16635

Duncansville

18960

Sellersville

19149

Philadelphia

19152

Philadelphia

19438

Harleysville

19611

West Reading

20852

Rockville

27612

Raleigh

29407

Charleston

29485

Summerville

30033

Decatur

30080

Smyrna

30342

Atlanta

32216

Jacksonville

32720

DeLand

33026

Pembroke Pines

33143

Miami

33321

Tamarac

33351

Sunrise

33418

Palm Beach Gardens

33484

Delray Beach

33606

Tampa

33709

St. Petersburg

34613

Brooksville

35801

Huntsville

36608

Mobile

37404

Chattanooga

37620

Bristol

38119

Memphis

40509

Lexington

40536

Lexington

45219

Cincinnati

45408

Dayton

46202

Indianapolis

48910

Lansing

53562

Middleton

60611

Chicago

60612

Chicago

63117

St Louis

64114

Kansas City

73103

Oklahoma City

73112

Oklahoma City

74104

Tulsa

75231

Dallas

78205

San Antonio

78756

Austin

80218

Denver

85016

Phoenix

89106

Las Vegas

92108

San Diego

92705

Santa Ana

92801

Anaheim

94598

Walnut Creek

95825

Sacramento

06416

Cromwell

02115

Boston

02462

Newton

08021

Clementon

02886

Warwick

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00424892 - Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome | Biotech Hunter | Biotech Hunter